Aardvark Therapeutics opened lower at $1.58, compared with its previous close of $1.59. In the last trading session, the stock traded between $1.51 and $1.59. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Aardvark Therapeutics is now worth
$ 10.80
Resulting in a loss of
$ 89.20 (89.20%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.05 (-2.83%)
Day High
$1.59
Day Low
$1.51
Day Open
$1.58
Prev Close
$1.59
Volume
1,76,527
1W Return
23.50%
1M Return
-65.38%
3M Return
-78.38%
6M Return
-72.99%
1Y Return
-86.03%
Market Cap ($ Mn)
34
PE Ratio
-
PB Ratio
1.69
PEG Ratio
-
ROE
-62.33%
ROCE
-53.17%
EPS (TTM)
-
1 Week
23.50%
1 Month
-65.38%
3 Months
-78.38%
6 Months
-72.99%
9 Months
-87.81%
Pomerantz files Aardvark class action; lead plaintiff deadline today
Pomerantz LLP filed a class action against Aardvark Therapeutics alleging misleading safety claims about ARD-101. Lead plaintiff motion deadline is October 13, 2026, for investors who purchased stock between February 13, 2025 and May 14, 2026. Stock declined 71.4% from IPO price of $16.00 to $4.57 following FDA clinical hold and trial pause. Complaint cites false statements regarding ARD-101 being 'gut-restricted' and 'well-tolerated' despite cardiac observations.
1mo agoAardvark Therapeutics grants 60,000 stock options to new employee
Aardvark Therapeutics granted a stock option for 60,000 shares to a new employee on October 1, 2026. The option has an exercise price of $5.27, matching the closing stock price on the grant date. The award was made under the 2025 Inducement Equity Incentive Plan per Nasdaq Listing Rule 5635(c)(4). Vesting occurs over four years, starting with 25% after one year and continuing monthly.
1mo agoBragar Eagel joins Aardvark securities lawsuit ahead of Oct 13 deadline
Bragar Eagel & Squire joins Hagens Berman and others in suing Aardvark Therapeutics. Lead plaintiff deadline for Aardvark class action is October 13, 2026. Stock dropped 56.2% after HERO trial pause and 32.1% after FDA clinical hold. Complaint alleges omission of cardiac safety data for drug candidate ARD-101.
1mo agoGrabar Law probes fiduciary duty claims at Aardvark, Flotek, GoDaddy, and Simply Good Foods
Grabar Law Office investigates fiduciary duty breaches at Aardvark Therapeutics, Flotek Industries, GoDaddy Inc., and Simply Good Foods. Aardvark faces claims after FDA clinical hold on ARD-101; stock fell 56% then 32.1%. Flotek terminated $400 million PREPA project due to consortium issues and oversight board revocation. GoDaddy bookings growth slowed to 5% amid undisclosed promotional pricing strategies. Simply Good Foods accused of hiding OWYN integration failures and margin erosion.
2mo agoAardvark Therapeutics Q2 EPS of $(0.66) beats $(0.91) estimate
Aardvark Therapeutics beat Q2 EPS estimates with a loss of $(0.66) per share versus the expected $(0.91). The company reported a flat net loss of $14.4 million, driven by lower R&D spend after halting its ARD-101 trials, partially offset by higher G&A costs.
3mo agoHC Wainwright reiterates Neutral on Aardvark Therapeutics
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Neutral rating on Aardvark Therapeutics with a $6 price target. The stock trades on NASDAQ under the symbol AARD.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 2 years ago in Aardvark Therapeutics is now worth
$ 10.80
Resulting in a loss of
$ 89.20 (89.20%)
Note: Past profits do not guarantee future returns.
